Insmed (INSM) Cash from Investing Activities (2010 - 2026)
Insmed (INSM) posted quarterly Cash from Investing Activities of $265.5 million for Q1 2026, up 230.2% year-over-year from $80.4 million in Q1 2025, and down 31.81% quarter-over-quarter from $389.4 million in Q4 2025.
Insmed (INSM) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Insmed's Cash from Investing Activities history runs 17 years deep, the most recent figure standing at $265.5 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 230.2% year-over-year to $265.5 million; the TTM figure through Mar 2026 stood at $120.5 million (up 115.1% YoY), while the FY2025 annual figure was -$64.6 million, up 88.93% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $265.5 million, down from $389.4 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $389.4 million in Q4 2025, with the low at -$1.0 billion in Q3 2024.
- The 5-year median for Cash from Investing Activities is $20.3 million (2022), against an average of -$37.7 million.
- Peak annual rise in Cash from Investing Activities reached 7207.71% in 2024, while the deepest fall reached 14140.45% in 2024.
- Insmed's Cash from Investing Activities stood at $20.3 million in 2022, then plunged by 91.12% to $1.8 million in 2023, then soared by 7207.71% to $131.8 million in 2024, then soared by 195.55% to $389.4 million in 2025, then tumbled by 31.81% to $265.5 million in 2026.
- Business Quant data shows INSM's Cash from Investing Activities at $265.5 million in Q1 2026, $389.4 million in Q4 2025, and -$762.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 281.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.51 Mn |
| Jun 30, 2026 | 24.51 Mn |
| Mar 31, 2026 | 265.52 Mn |
| Mar 31, 2026 | 265.52 Mn |
| Dec 31, 2025 | 389.41 Mn |
| Dec 31, 2025 | 389.41 Mn |
| Sep 30, 2025 | -762.23 Mn |
| Sep 30, 2025 | -762.23 Mn |
| Jun 30, 2025 | 227.84 Mn |
| Jun 30, 2025 | 227.84 Mn |
| Mar 31, 2025 | 80.41 Mn |
| Mar 31, 2025 | 80.41 Mn |
| Dec 31, 2024 | 131.76 Mn |
| Dec 31, 2024 | 131.76 Mn |
| Sep 30, 2024 | -1.00 Bn |
| Sep 30, 2024 | -1.00 Bn |
| Jun 30, 2024 | -6.78 Mn |
| Jun 30, 2024 | -6.78 Mn |
| Mar 31, 2024 | 295.32 Mn |
| Mar 31, 2024 | 295.32 Mn |